Peony-Glycyrrhiza Decoction (PGD) for Antipsychotic-induced Hyperprolactinemia in Patients With Schizophrenia

Schizophrenia Clinical Trial

— PGD-RCT  

Official title:

The Herbal Medicine Peony-Glycyrrhiza Decoction (PGD) as an Adjunctive Therapy to Treat Antipsychotic-induced Hyperprolactinemia in Patients With Schizophrenia: a Double-blind, Randomized, Placebo-controlled Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01852331
• Other study ID #: UW 11-274
• Status: Completed
• Phase: Phase 2
• First received: May 6, 2013
• Last updated: May 6, 2015
• Start date: January 2013
• Est. completion date: November 2014

Study information

• Verified date: May 2015
• Source: The University of Hong Kong
• Contact: n/a
• Is FDA regulated: No
• Health authority: Hong Kong: Department of Health
• Study type: Interventional

Clinical Trial Summary

The investigators hypothesize that Peony-Glycyrrhiza Decoction (PGD) adjunctive therapy could reduce the incidence of prolactin (PRL)-related adverse events in patients with schizophrenia and suppress antipsychotic-induced elevation of PRL levels.

This is a placebo-controlled trial conducted in schizophrenic patients to determine whether PGD adjunctive treatment could produce greater biochemical and clinical improvement on hyperprolactinemia (hyperPRL) compared to placebo treatment.

Description:

Schizophrenia is a severe mental illness that affects 0.7-1.1% of the worldwide population. Most patients who develop a chronic course with frequent relapses and exacerbation of psychosis are required to have long-term treatment. The clinical outcomes of antipsychotic pharmacotherapy are limited, largely due to various adverse side effects. Hyperprolactinemia (hyperPRL) is the most challenging among them. Dopamine agonists may be used for hyperPRL if it does not improve after the reduction of antipsychotic doses. However, this may aggravate psychosis and abnormal involuntary movements, which may be a greater risk than hyperPRL itself.

Chinese herbal medicine called Peony-Glycyrrhiza Decoction (PGD) has been widely introduced into the treatment of various conditions associated with hyperPRL in China and Japan. In our series of in-vitro experience it was found that PGD can significantly suppress PRL concentration in the cultured medium in a dose-dependent manner. Our recent open-labelled pilot study demonstrated that PGD significantly suppressed risperidone-induced elevation of blood PRL levels and produced a greater improvement on hyperPRL-related symptoms compared to dopamine agonist bromocriptine. Empirical and experimental evidence also confirmed that PGD and its individual herbal preparations possess a high safety profile.

The encouraging results obtained from our laboratory and clinical pilot studies, together with findings of previous studies, have warranted an extensive controlled trial to further determine PGD as an effective therapy for the treatment of antipsychotic-induced hyperPRL.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 103
• Est. completion date: November 2014
• Est. primary completion date: April 2014
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 60 Years

Eligibility

Inclusion Criteria:

• have a primary diagnosis of schizophrenia or schizoaffective disorder based on International Classification of Diseases (10th edition);

• under antipsychotic medications for at least three months and current conditions are stable, indicated by no difficulty to communicate with investigators and give informed consent;

• have developed at least one overt hyperPRL-associated symptom, including oligomenorrhoea (infrequent, irregularly timed episodes of bleeding occurring at intervals of more than 35 days from the previous menstrual cycle), amenorrhoea (the absence of menstruation for three menstrual cycles or 6 months), galactorrhea, decreased libido, anorgasmia or erectile dysfunction; and

• serum PRL levels are >24 ng/ml (or 1043.472 pmol/l) in female or >19 ng/ml (or 826.082 pmol/l) in male.

Exclusion Criteria:

• unstable medical conditions;

• suicidal ideas or attempts or aggressive behavior;

• history of alcoholism in the past one year, characterized by compulsive and uncontrolled consumption of alcohol, despite the realization of its negative effects on health, relationship, and social standing;

• history of drug abuse in past one year;

• currently treated with Chinese medicine or other natural products;

• allergic history of herbal medicine;

• pre-existing hyperPRL symptoms not associated with antipsychotic treatment; and

• pregnant and lactating women and those who refuse to use contraception during the study.

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Hyperprolactinaemia
• Hyperprolactinemia
• Schizophrenia
• Schizophrenic Disorder

Intervention

Drug:
• PGD granules
The preparation of Peony-Glycyrrhiza Decoction (PGD) granules is in compliance with Pharmacopoeia of the People's Republic of China and Good Manufacturing Practice (GMP). Briefly, sliced, broiled Paeoniae Alba Radix and Glycyrrhizae Radix in a ratio of 1:1 in weight will be immersed and boiled in an 8-fold volume of distilled water for 2.5 hours. This process will be repeated twice. The extract solution will be pooled and concentrated into granule form. Weight of the resulting granules contained in two 9g-sachet packs (to be taken in one day) is equivalent to 45 g raw herbal materials which are supplied for one day.
• Placebo
The placebo granules are prepared to be identical to PGD granules in smell, taste and color.

Locations

Country	Name	City	State
China	Beijing Anding Hospital	Beijing
China	Department of Psychiatry, Queen Mary Hospital	Hong Kong
China	Department of Psychiatry, Kowloon Hospital	Kowloon
China	Xijing Hospital	Xian	Shanxi

Sponsors (5)

Lead Sponsor	Collaborator
The University of Hong Kong	Capital Medical University, Kowloon Hospital, Hong Kong, Queen Mary Hospital, Hong Kong, Xijing Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Changes from baseline serum prolactin levels at 8 weeks and 16 weeks	Serum concentrations of serum prolactin will be measured using chemiluminescent immunoassay (CLIA).	baseline, week 8 and week 16	No
Other	Changes from baseline serum estradiol levels at 8 weeks and 16 weeks	Serum concentrations of estradiol will be measured using chemiluminescent immunoassay (CLIA).	baseline, week 8 and week 16	No
Other	Changes from baseline serum testosterone levels at 8 weeks and 16 weeks	Serum concentrations of testosterone will be measured using chemiluminescent immunoassay (CLIA).	baseline, week 8 and week 16	No
Primary	Changes from baseline Positive and Negative Syndrome Scale (PANSS) at 8 weeks and 16 weeks	The severity of psychotic symptoms will be assessed using the Positive and Negative Syndrome Scale (PANSS)	baseline, week 8 and week 16	No
Primary	Changes from baseline Clinical Global Impression (CGI) score at 8 weeks and 16 weeks	The severity of psychotic symptoms will be assessed using the Clinical Global Impression (CGI).	baseline, week 8 and week 16	No
Primary	Changes from baseline Simpson-Angus Rating Scale (SAS) at 8 weeks and 16 weeks	The Simpson-Angus Rating Scale (SAS) will be used to evaluate antipsychotic-induced abnormal involuntary movement symptoms.	baseline, week 8 and week 16	No
Primary	Changes from baseline Abnormal involuntary movement scale (AIMS) at 8 weeks and 16 weeks	The abnormal involuntary movement scale (AIMS) will be used to evaluate antipsychotic-induced abnormal involuntary movement symptoms.	baseline, week 8 and week 16	No
Secondary	Change from baseline scores of Prolactin Related Adverse Event Questionnaire (PRAEQ) at 8 weeks and 16 weeks	Menstrual disturbances, breast symptoms and penile function will be assessed using the Prolactin Related Adverse Event Questionnaire (PRAEQ).	baseline, week 8 and week 16	Yes
Secondary	Change from baseline scores of Udvalg for Kliniske Undersøgelser Side Effect Rating Scale (UKU) at 8 weeks and 16 weeks	Other adverse effects will be assessed using the Udvalg for Kliniske Undersøgelser Side Effect Rating Scale (UKU).	baseline, week 8 and week 16	Yes